TAIYO Pharma Co., Ltd. entered into an agreement to acquire marketing and manufacturing rights of 13 long-term listed products from Chugai Pharmaceutical Co., Ltd. (TSE:4519) and F. Hoffmann-La Roche Ltd on November 14, 2017. The 13 products covered by the agreement will continue to be marketed under the Chugai brand to ensure uninterrupted supply during the handover period. The marketing and manufacturing rights will be transferred to TAIYO Pharma Co., Ltd. on a step-by-step basis, starting from April 2018. The transfer of products is not expected to have a material impact on the consolidated financials of Chugai Pharmaceutical Co., Ltd. for the fiscal year ending December 2017. TAIYO Pharma Co., Ltd. completed the acquisition of marketing and manufacturing rights of 13 long-term listed products from Chugai Pharmaceutical Co., Ltd. (TSE:4519) and F. Hoffmann-La Roche Ltd for ¥21.3 billion on January 5, 2018. The consideration has been paid and the relevant closing conditions have been fulfilled.